Board of Directors
Our directors bring extensive expertise in corporate strategy, health care and venture capital, and have led or financed biopharma companies at all stages of development, from startup through commercialization. Their insights have been invaluable and will continue to guide Rodin through our next phases of growth.
Bruce Booth, D.Phil, Chairman Partner, Atlas Venture
Bruce Booth is a partner at Atlas Venture. In addition to chairing the board of directors at Rodin, Bruce is currently chairman of AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics, miRagen Therapeutics (NASDAQ:MGEN), Nimbus Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and also serves on the boards of Lysosomal Therapeutics and Magenta Therapeutics (NASDAQ:MGTA). He serves as an advisor in various capacities to UCB, Takeda and The Gates Foundation. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), and a number of other ventures. Bruce also serves on the board of the National Venture Capital Association. Bruce is a coauthor on numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. He also blogs about biotech and venture capital topics at LifeSciVC, which is syndicated on Forbes. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. Bruce received his B.S. in biochemistry from Penn State University and his D.Phil. (Ph.D.) in molecular immunology from Oxford University, where he was a British Marshall Scholar.
Kees Been, MBA President & CEO, Lysosomal Therapeutics
Kees Been is the founder, president and CEO of Lysosomal Therapeutics, a startup dedicated to innovation in neurodegeneration research. Kees was formerly the president and CEO of EnVivo Pharmaceuticals, which he led from an early-stage startup to a respected CNS company with a broad pipeline of NCE drug compounds. Previously, he served as CEO of Bionaut Pharmaceuticals, a small-molecule drug discovery company focused on oncology. He also spent four years at Biogen, first as senior vice president of business development, and later as senior vice president of the oncology business unit, which was sold to Idec. Kees has a master’s degree in molecular biology and process engineering from Wageningen University & Research in the Netherlands and an MBA from the European Institute of Business Administration (INSEAD).
John Creecy, M.S. CEO & Director, Remeditex Ventures
John Creecy is CEO and a director of Remeditex Ventures. He previously served as president and CEO of Hunt Petroleum Corporation, an oil and gas exploration and production company. Prior to that, he served as chief operating officer of The Hodges Companies, Inc., a family holdings company. For more than 20 years, John has served in various board positions within the All Saints Health System, the UT Southwestern Medical Center and Baylor Health Systems. He currently serves as chairman of the Baylor Scott White All Saints board in Fort Worth, Texas. John received his bachelor’s degree in accounting from Texas Tech University and an M.S. in tax from the University of North Texas. He is also a former certified public accountant and a member of various business and civic organizations in Dallas, Texas.
Jason Hong, Ph.D. Managing Director, Third Point LLC
Jason Hong is a managing director at Third Point LLC, an event-driven hedge fund based in New York City. At Third Point, he is responsible for public and private investments across all health care subsectors. Before joining Third Point, Jason worked as a vice president at Goldman Sachs, as portfolio manager at Polygon Investment Partners and as an associate analyst at Sanford C. Bernstein. Prior to working at Sanford C. Bernstein, Jason spent four years as an engagement manager at McKinsey & Company, where he worked with global health care companies in the areas of business development, post-merger integration and clinical program development. Jason holds a Ph.D. in chemistry from Harvard University and a B.S. with honors in chemistry from the California Institute of Technology.
Adam Rosenberg President & CEO, Rodin Therapeutics
Adam Rosenberg joined Rodin in September 2015 as president and chief executive officer. He has co-founded a number of innovative companies in Boston and Cambridge, including Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology to discover new treatments for CNS disorders; Clean Membranes, a nanomaterials company based on MIT technology; Link Medicine, a company focused on developing novel disease-modifying neurodegenerative treatments; and Faber Law Group, a boutique business law firm centered on the biotechnology sector. Previously, Adam was a principal with Ovation Capital Partners. Adam currently serves on the board of directors of Adeo Health Sciences, a venture-backed company focused on enabling the early introduction of allergens for infants. He holds a B.A. from Whittier College and a J.D. from the University of Virginia School of Law.
Samantha Singer, M.S., MBA Entrepreneur in Residence, Third Rock Ventures
Samantha Singer joined Third Rock Ventures as an entrepreneur in residence in December 2018. Previously, she was the chief operating officer of the Broad Institute of MIT and Harvard, where she oversaw critical teams pertaining to finance, operations and strategic partnerships at the institute. Samantha has extensive experience in corporate strategy and organizational effectiveness, having spent six years as vice president for corporate strategy and chief of staff for the CEO at Biogen Idec, where she led corporate strategy efforts and oversaw major operations initiatives abroad. Before her time at Biogen Idec, Samantha was a management consultant, first in the health care practice area at the Boston Consulting Group, and then in an independent consulting partnership focused on biotech companies and biomedical research centers. She holds an M.S. in molecular biology from The Rockefeller University and an MBA from Harvard Business School.
Clay Thorp, MPP Co-founder, Hatteras Venture Partners
Clay Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena, including Hatteras in 2000. Since co-founding Hatteras, Clay has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. He has led investments in life sciences across a range of fields, including biopharmaceuticals, medical devices, diagnostics and research informatics. Clay is currently chairman of PhaseBio Pharmaceuticals (PHAS) and chairman of GeneCentric Diagnostics, and serves on the boards of Clearside Biomedical (CLSD), Lysosomal Therapeutics, Artizan Biosciences and Orig3n. He holds an MPP from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill, where he remains a member of the chancellor’s philanthropic committee and the board of visitors of the Lineberger Comprehensive Cancer Center.
Ben Robbins, M.D., MBA, Observer Venture Partner, GV
Ben Robbins is a venture partner at Google Ventures and a medical resident in psychiatry at Massachusetts General Hospital and McLean Hospital. He is the co-founder of a company to improve drug adherence at a community health center in Boston and a nonprofit to operate a school for AIDS orphans in Tanzania, where he also worked closely with Students for the Advancement of Learning and Medical Aid in Tanzania. Robbins received his B.A. with honors from Dartmouth College, his MBA from Harvard Business School and his M.D. from Harvard Medical School. He has been recognized multiple times for his social impact work and is a recipient of the Harvard Medical School Dean’s community service award, the Harvard Medical School Agents of Change seed grant, the Harvard Medical School Master Scholar scholarship and the Harvard Business School Social Enterprise fellowship.